Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus chemotherapy as neoadjuvant and adjuvant therapy for locally advanced oral cancer with oral submucous fibrosis
ChiCTR2500115376Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab in mouth cancer and Oral submucous fibrosis (OSF), sponsored by Hunan Cancer Hospital. Primary endpoint: Major pathological response. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
penpulimab
03
Conditions
mouth cancerOral submucous fibrosis (OSF)
Beyond the preview
Go deeper on ChiCTR2500115376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115376.